Skip to main content
. 2020 Apr 20;17(8):2825. doi: 10.3390/ijerph17082825

Table 2.

Multivariable Cox proportional hazards model for comorbidities and survival analysis.

Variable Alcoholic Cirrhosis Non-Alcoholic Cirrhosis
Unadjusted Hazard Ratio a Adjusted Hazard Ratio Unadjusted Hazard Ratio a Adjusted Hazard Ratio
Risk Ratio 95% CI p-Value Risk Ratio 95% CI p-Value Risk Ratio 95% CI p-Value Risk Ratio 95% CI p-Value
Sex
Male 0.703 0.371–1.335 0.282 0.777 0.399–1.512 0.458 1.114 1.008–1.232 0.034 1.241 1.119-1.376 <0.001
Female (reference)
Age (years)
40–49 (reference)
50–59 1.255 0.877–1.795 0.214 1.335 0.923–1.930 0.124 1.070 0.883–1.297 0.489 1.114 0.918–1.351 0.275
60–69 0.793 0.465–1.353 0.395 0.848 0.489–1.472 0.559 1.258 1.041–1.521 0.017 1.344 1.105–1.635 0.003
>69 2.541 1.540–4.193 <0.001 2.004 1.115–3.603 0.020 2.487 2.104–2.939 <0.001 2.675 2.229–3.212 <0.001
Comorbidity
Coronary heart disease 1.098 0.700–1.723 0.685 1.170 0.703-1.948 0.546 1.129 1.014-1.257 0.027 0.886 0.785-1.000 0.050
Cerebrovascular disease
Hemorrhage 1.799 0.883–3.666 0.106 1.578 0.732–3.400 0.244 1.356 1.077–1.706 0.01 1.377 1.090–1.738 0.007
Ischemia 1.279 0.692–2.361 0.432 0.879 0.439–1.758 0.715 1.221 1.071–1.393 0.003 0.950 0.827–1.092 0.470
Hypertension 0.845 0.614–1.162 0.300 0.684 0.471–0.994 0.046 1.059 0.960–1.167 0.253 0.783 0.698–0.878 <0.001
Heart failure 1.393 0.754–2.571 0.290 0.981 0.477–2.016 0.958 1.510 1.328–1.715 <0.001 1.136 0.987–1.308 0.076
Diabetes mellitus 0.958 0.683–1.343 0.802 1.056 0.732–1.524 0.771 1.047 0.949–1.156 0.360 1.090 0.981–1.212 0.110
Chronic kidney disease 2.137 1.488–3.070 <0.001 2.276 1.520–3.409 <0.001 1.881 1.698–2.084 <0.001 1.751 1.571–1.951 <0.001
Hyperlipidemia 0.452 0.293–0.699 <0.001 0.447 0.282–0.708 <0.001 0.574 0.505–0.653 <0.001 0.571 0.499–0.652 <0.001
Chronic obstructive pulmonary disease 1.227 0.800-1.883 0.348 1.240 0.789-1.951 0.351 1.346 1.205-1.502 <0.001 0.994 0.883-1.119 0.920

a Adjustments were made for sex, age, residence, income, coronary artery disease, cerebrovascular disease, hypertension, heart failure, diabetes mellitus, chronic kidney disease, hyperlipidemia, and chronic obstructive pulmonary disease.